Patents by Inventor Longwu Qi

Longwu Qi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240109868
    Abstract: The present disclosure relates to an EP300/CBP modulator represented by formula I, a preparation method therefor and use thereof.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 4, 2024
    Inventors: Xiaolin LI, Longwu QI, Shusen XU, Jianbo BIE
  • NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES
    Publication number: 20230338409
    Abstract: The invention belongs to the technical field of medicine, and particularly relates to nucleoside drugs for the treatment or prevention of coronavirus infection and uses thereof. The present invention also relates to a method for preparing prodrugs of a nucleoside drug. The nucleoside drugs of formula (I) or (II) disclosed herein are more suitable for oral administration to subjects in need as compared to other nucleoside drugs, such as remdesivir for injection.
    Type: Application
    Filed: April 25, 2023
    Publication date: October 26, 2023
    Inventors: Xiaolin LI, Longwu QI, Shusen XU, Nana DU
  • PBD CONJUGATES FOR TREATING DISEASES
    Publication number: 20200323991
    Abstract: The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.
    Type: Application
    Filed: March 29, 2017
    Publication date: October 15, 2020
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON, Longwu QI, Ning ZOU, Kevin Yu WANG, Albert E. FELTEN, Garth L. PARHAM, Fei YOU, Hari Krishna R. SANTHAPURAM, Spencer J. HAHN, Joseph Anand REDDY, Yingjuan J. LU, Leroy W. WHEELER, II
  • CONJUGATES FOR TREATING DISEASES
    Publication number: 20200289659
    Abstract: The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 17, 2020
    Inventors: Iontcho Radoslavov Vlahov, Christopher Paul Leamon, Longwu QI, Yingcai Wang, Kevin Yu Wang, Ning Zou, Albert E. Felten
  • Conjugates for treating diseases
    Patent number: 10624972
    Abstract: The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: April 21, 2020
    Assignee: Endocyte, Inc.
    Inventors: Iontcho Radoslavov Vlahov, Christopher Paul Leamon, Longwu Qi, Yingcai Wang, Kevin Yu Wang, Ning Zou, Albert E. Felten
  • FOLATE CONJUGATE FOR USE IN TARGETING TUMOR ASSOCIATED MACROPHAGES
    Publication number: 20200038514
    Abstract: Methods are provided for treating cancers using a conjugate herein described as Conjugate 5, or a pharmaceutically acceptable salt thereof. Methods for treating cancers using Conjugate 5, or a pharmaceutically acceptable salt thereof, to target tumor associated macrophages are also described.
    Type: Application
    Filed: September 14, 2017
    Publication date: February 6, 2020
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON, Longwu QI, Ning ZOU, Kevin Yu WANG, Albert E. FELTEN, Garth L. PARHAM, Fei YOU, Hari Krishna R. SANTHAPURAM, Spencer J. HAHN, Joseph Anand REDDY, Yingjuan J. LU, Leroy W. WHEELER, II
  • CONJUGATES FOR TREATING DISEASES
    Publication number: 20180228914
    Abstract: The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.
    Type: Application
    Filed: March 13, 2015
    Publication date: August 16, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON, Longwu QI, Yingcai WANG, Kevin Yu WANG, Ning ZOU, Albert E. FELTEN
  • 3-aryl-substituted quinazolones, and uses thereof
    Patent number: 8575143
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: November 5, 2013
    Assignee: Prolexys Pharmaceuticals, Inc.
    Inventors: Longwu Qi, Raj Gopal Venkat, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Quinoxaline derivatives as antitumor agents
    Patent number: 8518959
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: August 27, 2013
    Assignee: Prolexys Pharmaceuticals, Inc.
    Inventors: Robert R. Becklin, Cindy Lou Chepanoske, John M. Peltier, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah, Keith Simmon, Brent R. Stockwell, Raj Gopal Venkat, Moritz von Rechenberg, Eugene Y. Zhen
  • FOLATE TARGETING OF NUCLEOTIDES
    Publication number: 20120022245
    Abstract: The present invention relates to compounds, compositions, kits, and methods of use in targeting nucleotides, such as siRNA's, to cancer cells or to immune system cells involved in inflammation. More particularly, the invention is directed to receptor binding ligand-nucleotide delivery conjugates for use in specifically targeting the conjugates to cancer cells or to immune system cells, methods of treatment with these conjugates, methods of preparation of these conjugates, and methods of reducing the expression of a gene in vitro or in vivo with the conjugates described herein.
    Type: Application
    Filed: October 16, 2009
    Publication date: January 26, 2012
    Applicants: PURDUE RESEARCH FOUNDATION, ENDOCYTE, INC.
    Inventors: Philip Stewart Low, Mini Thomas, Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Paul Joseph Kleindl, Longwu Qi
  • 3-Aryl-Substituted Quinazolones, and Uses Thereof
    Publication number: 20110092489
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Application
    Filed: December 22, 2006
    Publication date: April 21, 2011
    Applicant: Prolexys Pharmaceuticals ,Inc.
    Inventors: Longwu QI, Raj Gopal Venkat, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Erastin and erastin binding proteins, and uses thereof
    Patent number: 7615554
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: November 10, 2009
    Assignees: Prolexys Pharmaceuticals, Inc., Whitehead Institute for Biomedical Research, The Trustees of Columbia University in the City of New York
    Inventors: Robert Selliah, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Brent R. Stockwell, Raj Gopal Venkat
  • Quinoxaline Derivatives as Antitumor Agents
    Publication number: 20090214465
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Application
    Filed: January 25, 2006
    Publication date: August 27, 2009
    Applicants: PROLEXYS PHARMACEUTICALS, INC., WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Robert R. Becklin, Cindy Lou Chepanoske, John M. Peltier, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah, Keith Simmon, Brent R. Stockwell, Raj Gopal Venkat, Moritz von Rechenberg, Eugene Y. Zhen
  • Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
    Publication number: 20090170834
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reduction in rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 2, 2009
    Applicant: PROLEXYS PHARMACEUTICALS, INC.
    Inventors: Raj Gopal Venkat, Longwu Qi, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Erastin and erastin binding proteins, and uses thereof
    Publication number: 20060211683
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Application
    Filed: January 25, 2006
    Publication date: September 21, 2006
    Applicants: Prolexys Pharmaceuticals Inc., Whitehead Institute for Biomedical Research, The Trustees of Columbia University in the City of New York
    Inventors: Robert Selliah, Longwu Qi, Paul Robbins, Sudhir Sahasrabudhe, Brent Stockwell, Raj Venkat